Probiotics for Reduction of Infections With Clostridium Difficile in Critically Ill Patients

Clostridium Difficile Colonisation Clinical Trial

— ProbiEnt  

Official title:

Probiotics for Reduction of Colonisation With Clostridium Difficile in Antibiotic Treated Intensive Care Patients

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01687543
• Other study ID #: ProENT11
• Status: Terminated
• Phase: N/A
• First received: August 28, 2012
• Last updated: October 3, 2017
• Start date: June 2012
• Est. completion date: October 1, 2017

Study information

• Verified date: October 2017
• Source: Region Skane
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Symptoms of Clostridium difficile infection is almost always induced as a complication to the use of antibiotics. Most ICU patients are given antibiotics.

Probiotics has the ability to improve conditions in the gut and it has been shown in some smaller studies that overgrowth of C. difficile can be reduced or prevented.

In this study the intention is to show with sufficient statistical power that a mixture of two otherwise well studied probiotic strains reduces or prevents the incidence of emerging colonisation with C. difficile in critical ill patients on antibiotics.

Half of the patients will be given a mixture of Lactobacillus plantarum 299 and Lactobacillus plantarum 299v twice daily and the rest a placebo mixture.

Rectal swabs or faeces will be analysed for C.difficile and its toxins and the incidence of new cases will be compared for the two groups.

White blood cells (WBC´s), C reactive protein (CRP), lactate, urea, and creatinine will be followed daily as well as antibiotics, corticosteroids and all acid reducing medication.

Nutrition, enteral and total, and bowel habits will be recorded.

Description:

Infections with Clostridium difficile is considered to be the most frequent health care associated bacterial infection. Almost all cases are connected to the use of antibiotics.

The spectra of symptoms of infection reaches from loose stools to sepsis and death. It is estimated that about 5% of the population are carriers without symptoms.

Elderly people are more likely to be diagnosed with C. difficile infections and as about 50 % of ICU admissions (at least in Sweden) are patients aged 64 years or older C. difficile is also an ICU issue.

Probiotic bacteria given to antibiotic treated patients results in fever cases of infection with C. difficile as we and others have shown in some small studies. Due to a low statistical power in our former study this multicentre study is calculated to be large enough to fulfil statistical requirements.

Adult patients with an expected length of stay in intensive care for three days or more can be included.

Primary objective is to find emerging cases of colonisation with C. difficile and consequent symptoms of infection such as diarrhoea.

Cultures and toxin analyses will be taken at inclusion and every second day till day 13 and then every third or fourth day depending on length of ICU stay. Positive cases will be given antibiotics according to normal routines.

No other cultures are collected per protocol but all cultures will be recorded and results will be analysed in order to find any connection between treatment and reduction of secondary infections.

In our earlier small study we found an improved and normalised gut barrier function for those patients that were given probiotic bacteria compared to a worsened, scattered pattern for the placebo group. This is probably why we found that inflammatory parameters improved for the probiotics group while those parameters remained elevated for the control patients. The same goes for creatinine, urea and lactate. This is why we will record those parameters together with blood gas analyses in this expanded study.

Antibiotics and medication with corticosteroids, proton pump inhibitors or other acid reducing preparations, All nutritive prescriptions (enteral formulas and IV solutions as well as medical preparations containing glucose or fat) will be recorded and compared to actually given nutrients.

Bowel movements frequency and consistency will be recorded and compared between groups.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 25
• Est. completion date: October 1, 2017
• Est. primary completion date: June 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Anticipated need for intensive care 3 days or longer

• Patients condition allowing enteral nutrition to be started within 24 h from ICU admission

• Antibiotics on-going or planned

Exclusion Criteria:

• Known positive test for Clostridium difficile within the last week

• Known ulcers in the mouth, oropharynx, esophagus and stomach

• Known immune deficiencies

• Enteral nutrition contra indicated

• Pancreatitis as admission diagnosis at the hospital or at the ICU

• ICU admission earlier during this period of illness Patient being moribund

Related Conditions & MeSH terms

• Clostridium Difficile Colonisation
• Impact of Enteral Probiotics on Certain Lab Parameters

Intervention

Dietary Supplement:
• L. plantarum 299 and L. plantarum 299v (+maltodextrin)
A suspension of Lactobacillus plantarum 299 and Lactobacillus plantarum 299v together with maltodextrin is distributed to the patients twice a day.

Other:
• Maltodextrin
A suspension of maltodextrin (as placebo control) is distributed to the patients twice a day.

Locations

Country	Name	City	State
Sweden	Intensive Care Unit, Helsingborg Hospital	Helsingborg
Sweden	Intensive Care Unit, Kristianstad Central hospital	Kristianstad
Sweden	Lund University Hospital	Lund
Sweden	Dept of Anesthesia & Intensive Care, University Hospital of Norrland	Umeå

Sponsors (2)

Lead Sponsor	Collaborator
Region Skane	Lund University

Country where clinical trial is conducted

Sweden, 

References & Publications (1)

Klarin B, Wullt M, Palmquist I, Molin G, Larsson A, Jeppsson B. Lactobacillus plantarum 299v reduces colonisation of Clostridium difficile in critically ill patients treated with antibiotics. Acta Anaesthesiol Scand. 2008 Sep;52(8):1096-102. doi: 10.1111/j.1399-6576.2008.01748.x. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Differences in emerging cases of Clostridium difficile	Emerging cases of Clostridium difficile, identified as positive cultures and/or toxin tests	Throughout the ICU stay, expected mean LOS 10 days
Secondary	White blood cells	Samples taken at admission or inclusion and then daily	Throughout the ICU , expected mean LOS 10 days
Secondary	C Reactive Protein	Samples taken at admission or inclusion and then daily	Throughout the ICU , expected mean LOS 10 days
Secondary	Creatinine	Samples taken at admission or inclusion and then daily	Throughout the ICU , expected mean LOS 10 days
Secondary	Urea	Samples taken at admission or inclusion and then daily	Throughout the ICU , expected mean LOS 10 days
Secondary	Lactate	Samples taken at admission or inclusion and then daily	Throughout the ICU , expected mean LOS 10 days
Secondary	Ventilator days	Records are held for how long the patients require mechanical ventilation	Throughout the ICU stay, expected mean LOS 10 days
Secondary	Length of stay ICU	Length of stay is recorded for the ICU as well as for the Hospital stay	Length of ICU stay, about 10 days in accordance with a prior similar study
Secondary	Length of Hospital stay	Length of stay is recorded for the Hospital as well as for the ICU stay	Within six months from date of ICU admission
Secondary	Survival	For participating patients the status of survival or non survival at days 28 and 180 (six months) will be recorded	Six months
Secondary	Diarrhea and obstipation	As ICU patients tend to display diarrhea as well as obstipation the frequency and consistency of stools will be recorded.; Probiotics are anticipated to stabilise bowel function	Throughout the ICU stay, expected mean LOS 10 days

External Links

•   Producers of the study products